Novo Nordisk Shifts Strategy with Affordable Weight-Loss Pill Launch
Published on 01/12/2026 at 06:51 | Redaktion boerse-global.de
In a bold move to capture broader market share, Novo Nordisk has initiated a significant strategic pivot in the lucrative weight-loss drug sector. The Danish pharmaceutical giant is now introducing a far more affordable oral version of its Wegovy treatment to U.S. pharmacies, marking a departure from its previous reliance on high-margin injectable therapies. This calculated shift toward the mass market aims to secure decisive ground before competitors can respond.
The oral Wegovy formulation became available across approximately 70,000 U.S. pharmacies starting January 5, 2026. Its aggressive pricing structure is a central feature of the launch: the entry-level dose is priced at $149 per month for self-paying patients, with the maintenance dose set at Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
